🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to health experts.

A Global Challenge

The sexually transmitted infection are escalating worldwide, with estimates suggesting over 82 million instances per year. Especially elevated rates are reported in Africa and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the reality of growing infection rates, the spread of superbugs and the very limited treatment choices at this time.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts hope that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in the same week. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This approval represents a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Results and Worldwide Availability

Based on findings published in a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which involves two antibiotics. The research enrolled nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Doctors directly involved have shared positive views. Access to a easy-to-administer therapy like this is described as a "critical tool" for public health efforts. This is deemed crucial to alleviate the strain of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.